Zyprexa Fines Irrelevant In Actos Trial, Eli Lilly Says
Law360, New York (March 7, 2014, 5:25 PM EST) -- Eli Lilly & Co. argued Thursday that the first federal bellwether trial over the bladder cancer risks of diabetes drug Actos should exclude evidence about its fines for marketing the antipsychotic drug Zyprexa, saying it’s not relevant to negligent marketing claims over Actos.
In a response filed to the Louisiana federal court, Eli Lilly argued that the fines over Zyprexa stemmed from misdemeanor criminal violations, and not any finding of negligence. Its response followed a demand for sanctions earlier this week by plaintiffs Terrence and Susan Allen, who claimed a former Eli Lilly marketing executive lied to the court about not...
Stay ahead of the curve
In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.
Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
Create custom alerts for specific article and case topics and so much more!